Technical Analysis for ALRN - Aileron Therapeutics, Inc.

Grade Last Price % Change Price Change
F 1.2 0.84% 0.01
ALRN closed down 7.75 percent on Thursday, April 15, 2021, on 85 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical ALRN trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.84%
Oversold Stochastic Weakness 0.84%
Wide Bands Range Expansion -6.98%
Oversold Stochastic Weakness -6.98%
Wide Bands Range Expansion -8.40%
Oversold Stochastic Weakness -8.40%
Wide Bands Range Expansion -4.00%
Oversold Stochastic Weakness -4.00%
Fell Below 200 DMA Bearish -10.45%
180 Bearish Setup Bearish Swing Setup -10.45%
Older End-of-Day Signals for ALRN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 3 hours ago
Down 2 % about 3 hours ago
Down 1% about 3 hours ago
Up 3% about 3 hours ago
Up 2% about 3 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aileron Therapeutics, Inc. Description

Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Solid Tumors Cancers Inflammation Lymphoma Molecular Biology Tumor Cell Biology Peptides Metabolic Disease Metabolic Diseases Proteins Hematological Malignancies Oncogenes Treatment Of A Range Of Cancer P53 Tumor Suppressor Genes Tumor Suppressor

Is ALRN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.47
52 Week Low 0.46
Average Volume 2,132,502
200-Day Moving Average 1.37
50-Day Moving Average 1.62
20-Day Moving Average 1.44
10-Day Moving Average 1.34
Average True Range 0.13
ADX 32.17
+DI 10.33
-DI 28.71
Chandelier Exit (Long, 3 ATRs ) 1.37
Chandelier Exit (Short, 3 ATRs ) 1.54
Upper Bollinger Band 1.73
Lower Bollinger Band 1.15
Percent B (%b) 0.07
BandWidth 40.64
MACD Line -0.09
MACD Signal Line -0.08
MACD Histogram -0.016
Fundamentals Value
Market Cap 48.41 Million
Num Shares 40.7 Million
EPS -1.61
Price-to-Earnings (P/E) Ratio -0.74
Price-to-Sales 0.00
Price-to-Book 3.40
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.42
Resistance 3 (R3) 1.43 1.36 1.38
Resistance 2 (R2) 1.36 1.31 1.36 1.36
Resistance 1 (R1) 1.28 1.27 1.25 1.27 1.35
Pivot Point 1.21 1.21 1.20 1.21 1.21
Support 1 (S1) 1.13 1.16 1.10 1.12 1.03
Support 2 (S2) 1.06 1.12 1.06 1.02
Support 3 (S3) 0.98 1.06 1.00
Support 4 (S4) 0.97